C4 Therapeutics To Present New Preclinical Data On Highly Selective Orally Bioavailable BiDAC Degraders At The American Association For Cancer Research Annual Meeting 2024

Author: Benzinga Newsdesk | March 05, 2024 05:35pm

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.

 

Details of the posters are as follows:

Title: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis

Abstract Number: 1658

Session Date and Time: Monday April 8, 2024 9:00 AM - 12:30 PM PT

Location: Poster Section 14

Session Title: Cell Signaling Components as Therapeutic Targets

Presenter: Bridget Kreger, Ph.D., principal scientist, biology

Title: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset of multiple myeloma cell line models and synergistic when combined with pomalidomide or dexamethasone

Abstract Number: 6064

Session Date and Time: Tuesday April 9, 2024 1:30 PM - 5:00 PM PT

Location: Poster Section 30

Session Title: Targeted Protein Degraders

Presenter: Laura Poling, Ph.D., director, biology

In November 2023, C4T made the strategic decision to discontinue clinical development of CFT8634 based on clinical data from the Phase 1 trial.

Posted In: CCCC